TY - JOUR
T1 - Chromatin modifying agents - The cutting edge of anticancer therapy
AU - Kwa, Faith A. A.
AU - Balcerczyk, Aneta
AU - Licciardi, Paul
AU - El-Osta, Assam
AU - Karagiannis, Tom C.
PY - 2011/7
Y1 - 2011/7
N2 - Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.
AB - Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.
UR - http://www.scopus.com/inward/record.url?scp=79959765942&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2011.05.012
DO - 10.1016/j.drudis.2011.05.012
M3 - Review Article
C2 - 21664485
AN - SCOPUS:79959765942
SN - 1359-6446
VL - 16
SP - 543
EP - 547
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 13-14
ER -